CA3180095A1 - Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) - Google Patents
Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) Download PDFInfo
- Publication number
- CA3180095A1 CA3180095A1 CA3180095A CA3180095A CA3180095A1 CA 3180095 A1 CA3180095 A1 CA 3180095A1 CA 3180095 A CA3180095 A CA 3180095A CA 3180095 A CA3180095 A CA 3180095A CA 3180095 A1 CA3180095 A1 CA 3180095A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- epha2
- patient
- tumor tissue
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038279P | 2020-06-12 | 2020-06-12 | |
| US63/038,279 | 2020-06-12 | ||
| PCT/GB2021/051451 WO2021250418A1 (en) | 2020-06-12 | 2021-06-11 | Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3180095A1 true CA3180095A1 (en) | 2021-12-16 |
Family
ID=76641715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3180095A Pending CA3180095A1 (en) | 2020-06-12 | 2021-06-11 | Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230233698A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4165414A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023529214A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230065231A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115698720A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021289095A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3180095A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL298868A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022015419A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021250418A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ731185A (en) | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| CA3091775A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| KR20220007098A (ko) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Ox40에 특이적인 이환식 펩티드 리간드 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0607450A2 (pt) * | 2005-02-04 | 2009-09-01 | Raven Biotechnologies Inc | anticorpos que se ligam a epha2 e métodos para sua utilização |
| CN101918844A (zh) * | 2007-06-18 | 2010-12-15 | 米迪缪尼有限公司 | 表达epha2和erbb2的细胞的协同治疗 |
| EP2223112A2 (en) * | 2007-12-21 | 2010-09-01 | Siemens Healthcare Diagnostics Inc. | Circulating epha2 receptor |
| JP6074574B2 (ja) | 2008-02-05 | 2017-02-08 | バイシクル セラピューティクス リミテッド | 方法及び組成物 |
| CA2847245A1 (en) * | 2011-09-09 | 2013-03-14 | Amgen Inc. | Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients |
| WO2016171242A1 (ja) * | 2015-04-24 | 2016-10-27 | 第一三共株式会社 | Ｅｐｈａ２の検出 |
| JP2019512477A (ja) * | 2016-03-16 | 2019-05-16 | メリマック ファーマシューティカルズ インコーポレーティッド | エフリン受容体ａ２（ｅｐｈａ２）のナノリポソーム標的化及び関連する診断 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| CN109700812A (zh) * | 2019-01-18 | 2019-05-03 | 厦门大学 | 一种治疗表达parp10的肝细胞癌的药物组合物及其应用 |
| US20220184222A1 (en) * | 2019-04-02 | 2022-06-16 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| CN114760988A (zh) * | 2019-11-27 | 2022-07-15 | 拜斯科技术开发有限公司 | 对EphA2具有特异性的双环肽配体和其用途 |
-
2021
- 2021-06-11 EP EP21735361.4A patent/EP4165414A1/en active Pending
- 2021-06-11 US US18/001,374 patent/US20230233698A1/en active Pending
- 2021-06-11 CA CA3180095A patent/CA3180095A1/en active Pending
- 2021-06-11 KR KR1020237001004A patent/KR20230065231A/ko active Pending
- 2021-06-11 CN CN202180042177.6A patent/CN115698720A/zh active Pending
- 2021-06-11 AU AU2021289095A patent/AU2021289095A1/en active Pending
- 2021-06-11 IL IL298868A patent/IL298868A/en unknown
- 2021-06-11 WO PCT/GB2021/051451 patent/WO2021250418A1/en not_active Ceased
- 2021-06-11 JP JP2022575977A patent/JP2023529214A/ja active Pending
- 2021-06-11 MX MX2022015419A patent/MX2022015419A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023529214A (ja) | 2023-07-07 |
| AU2021289095A1 (en) | 2023-01-05 |
| US20230233698A1 (en) | 2023-07-27 |
| CN115698720A (zh) | 2023-02-03 |
| WO2021250418A1 (en) | 2021-12-16 |
| KR20230065231A (ko) | 2023-05-11 |
| EP4165414A1 (en) | 2023-04-19 |
| IL298868A (en) | 2023-02-01 |
| MX2022015419A (es) | 2023-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298868A (en) | Treatment of diseases characterized by overexpression of hepatocyte receptor A2 that produces erythropoietin (EPHA2) | |
| AU2020319704B2 (en) | Heterotandem bicyclic peptide complex | |
| US12097237B2 (en) | Small molecule Ras inhibitors | |
| KR101513842B1 (ko) | 합성 펩타이드 아마이드와 그의 다이머 | |
| US9308236B2 (en) | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | |
| TWI247748B (en) | Peptide antiangiogenic drugs | |
| JP6961586B2 (ja) | α４β７インテグリンを標的とする環状ペプチド | |
| WO2013170066A1 (en) | Peptides for the treatment of cancer | |
| CA3086257A1 (en) | Bicyclic peptide ligands specific for epha2 | |
| CA2969908A1 (en) | Antibody drug conjugates with cell permeable bcl-xl inhibitors | |
| CN106715462A (zh) | α4β7整联蛋白硫醚肽拮抗剂 | |
| CA2970161A1 (en) | Bcl-xl inhibitory compounds and antibody drug conjugates including the same | |
| CN103396473A (zh) | Cxcr4受体化合物 | |
| CN115715201A (zh) | 葡萄糖雷公藤甲素缀合物及其用途 | |
| US20240287033A1 (en) | Degraders of tissue transglutaminase 2 (tg2) | |
| Panja et al. | Synthesis and anticancer properties of novel dolastatin 10 analogs featuring five-membered heterocyclic rings with a linkable group at the C-terminus | |
| EP4631956A1 (en) | Linker, linker-containing antibody drug conjugate, and preparation method therefor and use thereof | |
| US12612431B2 (en) | Cyclic compounds for treating cancer | |
| AU2023207537A1 (en) | Tsp1 inhibitor | |
| US20260008755A1 (en) | Inhibitors of protein arginine deiminase 1 and methods of preparation and use thereof | |
| Li et al. | Exploring substitution effects on the potential dominant conformations of NBF derivatives leading to functional conversion at the mu opioid receptor | |
| Anselmi | Peptidomimetic ligands for tuning integrin-mediated signalling: rational design, synthesis and theranostic applications | |
| HK1184363B (en) | Novel auristatin derivatives and use thereof | |
| HK1184363A1 (en) | Novel auristatin derivatives and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250606 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250606 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250606 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250609 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250609 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250609 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250819 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250819 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250819 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250819 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250819 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260520 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260520 |